Company Moves to Larger Headquarters and Expands Team as it Prepares for Commercialization of Clarifi™ Imaging System
IRVINE, Calif. — March 5, 2019 (BUSINESS WIRE) — Modulated Imaging, recognized leader in optical imaging solutions for non-invasive assessment of tissue health, announced today that it has officially changed its name to Modulim.
With the company entering the next stage of its growth, they are moving to a larger headquarters (2400 Barranca in Irvine, CA) and are actively expanding the sales, marketing, engineering, and clinical applications teams.
In keeping with the new name and headquarters, the company has also launched an enhanced and updated website, modulim.com.
“While paying homage to the effort we’ve already invested in our groundbreaking technology, the Modulim name is much more than a simple contraction of ‘Modulated Imaging,’” said David Cuccia, Ph.D., Modulim’s founding CEO and CTO. “It’s also a representation of our newly honed focus on point-of-care diagnostics. As we evolve and grow, we have become more than an imaging company. We’re also a software company, a data/analytics company, and a clinical solutions company, dedicated to helping clinicians prevent diabetic foot ulcers and other complications due to compromised circulation.”
“As we enter the next phase of our evolution,” added Richard Oberreiter, COO, “we are excited and driven by our mission — to deliver transformative optical imaging solutions that help clinicians diagnose and prevent vascular dysfunction, empowering people to live healthier, longer, more fulfilling lives. There is no clearer expression of that ambitious goal than the masthead of our new website; ‘an ounce of prevention is priceless.’”
Among the first big moves for Modulim under the new name will be the national launch of its groundbreaking Clarifi™ Imaging system. Powered by Modulim’s proprietary optical imaging technique, spatial frequency domain imaging (SFDI), Clarifi offers clinicians a fast, reliable, objective method of assessing tissue oxygen saturation and hemoglobin concentration and distribution in the tissue. The technology is able to provide clinicians with an early warning system for complications due to compromised circulation, including diabetic foot ulcers.
Modulim is a pioneer in subsurface optical imaging powered by SFDI, an advanced imaging technique co-invented by CEO and CTO David Cuccia, PhD. SFDI deciphers the reflection, absorbance, and scattering of light in tissue to more accurately measure key biomarkers for assessing tissue health. The proprietary technology helps clinicians identify compromised circulation and perfusion by measuring microvascular tissue oxygenation and hemoglobin concentration and distribution. As a result, the company’s solution can help clinicians identify patients with compromised circulation for earlier intervention. With widespread adoption, this approach could save thousands of limbs and lives, as well as billions of dollars in treatment costs. For more information, visit modulim.com.